In accordance with 35 U.S.C. § 287(a), the following table used in conjunction with the FDA-approved product labeling may be used to determine U.S. patents associated with the corresponding U.S. marketed product; additional patents may be pending in the U.S. and in other countries. The following list may not be all inclusive, and other products not listed here may be protected by one or more patents in the U.S. and additional countries.
PRODUCT
PATENT INFORMATION
FIASP® (insulin aspart recombinant)
8,324,157
GLUCAGEN® (glucagon [rDNA origin])
No unexpired patents
LEVEMIR® (insulin detemir [rDNA origin] injection)
5,750,497
NORDITROPIN® (somatropin [rDNA origin] injection)
6,899,699
RE 46,363
7,762,994
8,579,869
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,616,180
9,687,611
9,861,757
D729,930
D765,833
and
other patents pending
NOVOEIGHT® (Antihemophilic Factor [Recombinant])
6,100,061
6,475,725
6,936,441
7,094,574
8,080,414
8,084,251
8,084,252
8,329,465
8,399,620
9,982,033
NOVOLIN® 70/30 (70% NPH, human insulin isophane
suspension
[rDNA origin] and 30% human insulin, regular [rDNA origin])
No unexpired patents
NOVOLIN® N (insulin suspension isophane [rDNA
origin])
No unexpired patents
NOVOLIN® R (insulin human [rDNA origin])
No unexpired patents
NOVOLOG® (insulin aspart [rDNA origin] injection)
No unexpired patents
NOVOLOG® MIX 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection [rDNA origin])
No unexpired patents
NOVOSEVEN® RT (Coagulation Factor VIIa [Recombinant])
8,299,029
8,658,597
8,729,022
OZEMPIC® (semaglutide)
6,899,699
7,762,994
8,114,833
8,129,343
8,536,122
8,579,869
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,687,611
9,775,953
RE46,363
PRANDIMET® (repaglinide/metformin HCI)
No unexpired patents
PRANDIN® (repaglinide)
No unexpired patents
REBINYN® (Coagulation Factor IX (recombinant), glycoPEGylated)
7,138,371
7,416,858
7,473,680
8,404,809
8,632,770
8,791,070
RYZODEG®70/30 (insulin degludec and insulin aspart injection)
7,615,532
6,899,699
7,762,994
8,579,869
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,687,611
9,775,953
RE 46,363
SAXENDA® (liraglutide [rDNA origin] injection)
6,268,343
6,458,924
7,235,627
8,114,833
8,846,618
6,899,699
7,762,994
8,579,869
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,687,611
9,775,953
RE 46,363
TRESIBA® (insulin degludec injection)
7,615,532
6,899,699
7,762,994
8,579,869
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,687,611
9,775,953
RE 46,363
TRETTEN® (Coagulation Factor XIII A-Subunit [Recombinant])
Patents pending
VAGIFEM® (estradiol vaginal tablets)
7,018,992
VICTOZA® (liraglutide [rDNA origin] injection)
6,268,343
6,458,924
7,235,627
8,114,833
8,846,618
6,899,699
7,762,994
8,579,869
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,687,611
9,775,953
RE 46,363
9,968,659
XULTOPHY® 100/3.6 (insulin degludec and liraglutide injection)
6,268,343
6,458,924
6,899,699
7,235,627
7,615,532
RE46,363
8,672,898
8,684,969
8,846,618
8,920,383
8,937,042
9,108,002
9,132,239
9,457,154
9,486,588
7,762,994
8,579,869
9,687,611
9,775,953
AUTOCOVER®
6,855,129
7,553,293
8,075,522
8,728,027
FLEXPEN®
6,004,297
RE 41,956
RE 43,834
9,265,893
7,762,994
8,579,869
FLEXPRO®
6,899,699
RE46,363
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,687,611
D729,730
D765,833
7,762,994
8,579,869
9,775,953
FLEXPRO® PENMATE®
5,980,491
6,537,252
FLEXTOUCH®
6,899,699
RE46,363
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,687,611
D724,721
D734,450
D758,571
7,762,994
8,579,869
9,775,953
NOVOFINE® 32G
6,544,238
NOVOFINE® PLUS 32G
6,544,238
NOVOPEN® ECHO®
6,248,090
6,277,098
6,663,602
7,241,278
NOVOTWIST®
7,654,986
8,137,325
8,579,869
D675,316
7,762,994
PENFILL®
No unexpired patents
© 2015 Novo Nordisk All rights reserved. 0715-00027690-1 September 2015